Ebola hemorrhagic fever vaccine University of Tokyo goes to Japan's first clinical trial December 5th 15:55
A research group at the University of Tokyo announced that it will be the first clinical trial in Japan to inoculate a healthy person with the Ebola vaccine under development.
Ebola hemorrhagic fever is transmitted through contact with the patient's blood and body fluids, and the fatality rate is high at 25% or more. In the Democratic Republic of the Congo in central Africa, approximately 2,200 people have died since last August. "Public health emergency".
The research group of Prof. Yoshihiro Kawaoka of the University of Tokyo Institute of Medical Science held a press conference on the 5th and announced that a clinical trial to vaccinate people will start this month.
Vaccine is a non-toxic vaccine that has no effect on the genes involved in virus growth, and monkeys have been confirmed to be effective and safe in preventing infection.
In clinical trials, we plan to inoculate 30 healthy adult men twice to check if antibodies are available and there are no safety issues.
Ebola vaccine is being developed in each country, and last month a vaccine developed by an American pharmaceutical company was approved by a European regulatory authority, and WHO will push the vaccine in countries at risk of infection. It is announced.
Prof. Kawaoka is the first clinical trial of Ebola vaccine in Japan. “If Ebola hemorrhagic fever has entered the country, it will be necessary to promptly supply the vaccine to healthcare professionals. I think the significance of doing this is great. "